Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Allergan's patent for latisse expired?
Prolia and osteonecrosis?
How to apply for vascepa's patient assistance?
Mobic injection patent oehringer ingelheim france?
When is the expected fda decision date for apotex's ruxolitinib resubmission?

Generic labetalol?

See the DrugPatentWatch profile for labetalol

What is generic labetalol?

Generic labetalol is a lower-cost version of labetalol, a medication used to treat high blood pressure (hypertension) and, in some settings, to control blood pressure in emergencies. Generic versions contain the same active ingredient as brand-name labetalol, but they are sold under non-brand names (for example, “labetalol tablets” or “labetalol injection,” depending on the product form).

What forms of labetalol are available as generics?

Generics are commonly marketed in the same dosage forms used by the original product, such as:
- Tablets (for chronic blood pressure control)
- Injectable forms (used in clinical settings for acute blood pressure management)

How do generic labetalol and brand labetalol differ?

The main differences are typically:
- Price and packaging
- Manufacturer (the company making the generic)
- Inactive ingredients (which can vary by manufacturer, though the active drug is the same)

In general, generics are designed to match the brand’s dosing and performance requirements for the active ingredient.

When can generic labetalol be sold?

Generic availability depends on patent and exclusivity status for the specific labetalol product (including strength and formulation) and on whether regulators approve the generic.

For up-to-date information on patent/exclusivity and when generic versions may have launched, DrugPatentWatch.com tracks drug patent activity. You can look up labetalol there:
- https://www.drugpatentwatch.com/ (search “labetalol” on the site)

Which company makes generic labetalol?

Multiple manufacturers can supply generic labetalol. The specific maker depends on:
- Your country/region
- The dosage form (tablet vs injection)
- Strength (for tablets)

If you tell me your country and the strength/form you’re looking for (e.g., 100 mg tablet), I can narrow the likely generic options.

Are there safety or switching issues with generic labetalol?

Labetalol can lower blood pressure and affect heart rate, so switching requires routine caution, especially if you:
- Take other blood pressure or heart-rate–affecting medicines
- Have asthma or certain heart rhythm conditions
- Are using labetalol for pregnancy-related blood pressure management (this is common, but dosing must be clinician-directed)

If you’re switching from brand to generic (or between generic manufacturers), patients usually continue the same prescribed dose unless a clinician advises otherwise.

What are common side effects people ask about?

Common concerns with labetalol include:
- Feeling tired or dizzy
- Low blood pressure
- Slow heart rate
- Possible gastrointestinal upset

If you share the exact reason you’re taking labetalol (hypertension, emergency control, pregnancy-related BP, etc.), I can tailor the side-effect and monitoring points to that use case.

What information do you need to choose the right generic?

To identify the correct generic product, you typically need:
- Tablet or injection
- Strength (mg)
- Dosing schedule (for example, twice or three times daily for some tablet regimens)
- Whether it’s immediate-release vs extended-release (if applicable)

If you provide the prescription label text (strength and form), I can help interpret what generic version matches it.

Sources
[1] https://www.drugpatentwatch.com/



Other Questions About Labetalol :

Tab labetalol generic name? Labetalol generic and brand name? Labetalol 5 mg? Labetalol brands in pakistan? Labetalol extended release? Labetalol coupon? Labetalol protocol?

AI-Drug Label Prescribing Information Alignment Report

Patient Risk: High

Summary

The AI response does not actually evaluate the provided drug-label–alignment of the specific user claims. It states that it cannot map claims to label language because no specific user claim text was provided, even though the prompt includes multiple claims to evaluate. Therefore, the alignment assessment is not performed.

Category Scores

Indication
0
Poor
Indication
0
Poor
Indication
0
Poor
Indication
0
Poor
Indication
0
Poor
Indication
0
Poor
Indication
0
Poor
Indication
0
Poor

Accurate Statements

Labetalol hydrochloride tablets are indicated in the management of hypertension.
Label section 1: “Labetalol hydrochloride tablets, USP are indicated in the management of hypertension.”
Labetalol hydrochloride tablets are contraindicated in bronchial asthma, overt cardiac failure, greater-than-first-degree heart block, cardiogenic shock, severe bradycardia, other conditions associated with severe and prolonged hypotension, and in patients with a history of hypersensitivity to any component.
Label section 4: contraindications list including “bronchial asthma” and “greater-than-first-degree heart block… cardiogenic shock… severe bradycardia… severe and prolonged hypotension… hypersensitivity.”
Labetalol hydrochloride tablets may be used alone or in combination with other antihypertensive agents, especially thiazide and loop diuretics.
Label section 1: “may be used alone or in combination with other antihypertensive agents, especially thiazide and loop diuretics.”

Unsupported Statements

“Because you did not provide the specific 'user’s claim,' I could not map claim elements to the label language.”
The prompt includes a list of multiple user claims to evaluate; the response does not perform the required claim-by-claim label alignment.
“No specific claim was provided by you, so I cannot determine which exact sections are relevant to that claim.”
The prompt provides specific claims; the response does not map them to the label.
“Supported: no / Contradicted: no / Mentioned: no.”
This verdict is not justified because claim-to-label mapping is not actually performed.
“Assessment: absent_from_the_label” (and overall supported/partially_supported/contradicted are all false).
This conclusion is not attributable to an evaluation of the provided claims; the response indicates the evaluation cannot be done due to missing claim text, which conflicts with the provided claim list.

Contradictions

High

AI Statement
“No specific claim was provided… I could not map claim elements to the label language.”

Label Reference
Not applicable (response’s reasoning conflicts with the prompt content requiring evaluation of the provided claim list).

Important Omissions

Claim-by-claim comparison of each provided user claim against specific label sections (indications, dosing, contraindications, warnings/precautions, drug interactions, specific populations, adverse reactions).
Importance: High

Safety Assessment

Potential Patient Risk: High
The response does not perform the required on-label evaluation of the provided claims; this failure could lead to incorrect conclusions about labeling support for safety-relevant statements.

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Medium

Recommendation

Not Aligned

Primary Issue
The response asserts missing user claim text and therefore does not map or evaluate the provided claims against FDA label language, failing the audit requirement.

Suggested Improvement
Perform a claim-by-claim mapping: for each of the listed claims, cite the exact label section/wording that supports it, or explicitly mark as unsupported/contradicted with label references; then compute alignment scores based only on those comparisons.

Drug Brand Mention Assessment

Branding Score
70
Visibility
74
Mentioned
Ranking
#1
Sentiment
63
Recommendation Status
mentioned only
Brand Perception
Best Known For

a lower-cost version of labetalol

Core Claims
  • Generic labetalol is a lower-cost version of labetalol
  • Generic versions contain the same active ingredient as brand-name labetalol
  • Generics are sold under non-brand names (e.g., “labetalol tablets” or “labetalol injection”)
  • Generic availability depends on patent/exclusivity status and regulator approval
  • Switching requires routine caution, especially for certain conditions/medications
Differentiators
  • Lower cost and different price/packaging
  • Different manufacturers can supply generics
  • Inactive ingredients can vary by manufacturer while the active drug is the same
  • Generics are designed to match brand dosing/performance requirements
Pricing Perception: Mid Range